Severe Hypertriglyceridemia - Pipeline Insight, 2024

This “Severe Hypertriglyceridemia - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Severe Hypertriglyceridemia Understanding

Severe Hypertriglyceridemia: Overview

Hypertriglyceridemia is a common condition, which is defined as having a high level (above 150 mg/dL) of triglycerides, a type of fat, in the bloodstream. Hypertriglyceridemia can lead to conditions including atherosclerosis (hardening of the arteries), obesity, and insulin resistance, which all can contribute to increased risk of cardiovascular disease (CVD). There are more than 2.1 million adults in the United States with severe hypertriglyceridemia (SHTG), which is defined as having a triglyceride level over 500 mg/dL. In addition to increasing the risk of CVD, SHTG is also a known risk factor for acute pancreatitis, a life-threatening condition. Risk factors for SHTG can include genetic disorders, obesity, untreated diabetes, and certain medications. While SHTG often causes no noticeable symptoms, individuals with extremely high levels of triglycerides (greater than 2,000 mg/dL) can experience recurrent abdominal pain, nausea, vomiting, xanthomas (yellow-colored bumps on the skin), and acute pancreatitis. There are many ways to prevent and treat SHTG. Lifestyle changes that can impact SHTG include lowering fat and carbohydrate intake, reducing alcohol consumption, and quitting smoking. For some people, lifestyle changes aren’t enough to reduce triglycerides to the appropriate levels, leaving them at risk for additional complications. In these cases, there are pharmacological therapies that can reduce triglyceride levels to healthier levels

Severe Hypertriglyceridemia - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Severe Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Severe Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Severe Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Severe Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Severe Hypertriglyceridemia.
• In the coming years, the Severe Hypertriglyceridemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Severe Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Severe Hypertriglyceridemia treatment market. Several potential therapies for Severe Hypertriglyceridemia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Severe Hypertriglyceridemia market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Severe Hypertriglyceridemia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Severe Hypertriglyceridemia Emerging Drugs Chapters

This segment of the Severe Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Severe Hypertriglyceridemia Emerging Drugs

ARO-APOC3: Arrowhead Pharmaceuticals ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.

Olezarsen: Ionis Pharmaceuticals Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.

Severe Hypertriglyceridemia: Therapeutic Assessment

This segment of the report provides insights about the different Severe Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Severe Hypertriglyceridemia

There are approx. 10+ key companies which are developing the therapies for Severe Hypertriglyceridemia. The companies which have their Severe Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals, Inc.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Severe Hypertriglyceridemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Severe Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Severe Hypertriglyceridemia drugs.

Severe Hypertriglyceridemia Report Insights

• Severe Hypertriglyceridemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Severe Hypertriglyceridemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Severe Hypertriglyceridemia drugs?
• How many Severe Hypertriglyceridemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Severe Hypertriglyceridemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Severe Hypertriglyceridemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Severe Hypertriglyceridemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arrowhead Pharmaceuticals
• Ionis Pharmaceuticals, Inc.
• 89bio, Inc.
• Regeneron Pharmaceuticals
• Kowa Research Institute, Inc.
• Mochida Pharmaceutical
• Acasti Pharma Inc.
• NorthSea Therapeutics
• Matinas BioPharma

Key Products

• ARO-APOC3
• Olezarsen
• BIO89-100
• Evinacumab
• K-877
• Ethyl Icosapentate
• CaPre
• SEFA-1024
• MAT9001

This product will be delivered within 1-3 business days.